Novel treatment strategies for malignant melanoma : A new beginning?KASPER, Bernd; D'HONDT, Veronique; VEREECKEN, Pierre et al.Critical reviews in oncology/hematology. 2007, Vol 62, Num 1, pp 16-22, issn 1040-8428, 7 p.Article

Novel treatment strategies for soft tissue sarcomaKASPER, Bernd; GIL, Thierry; D'HONDT, Veronique et al.Critical reviews in oncology/hematology. 2007, Vol 62, Num 1, pp 9-15, issn 1040-8428, 7 p.Article

Maximum tolerated dose: clinical endpoint for a bygone era?TAKIMOTO, Chris H.Targeted oncology. 2009, Vol 4, Num 2, pp 143-147, issn 1776-2596, 5 p.Article

Neuropilin-1 is upregulated in hepatocellular carcinoma and contributes to tumour growth and vascular remodellingBERGE, Mathieu; ALLANIC, David; LEVY, Bernard I et al.Journal of hepatology. 2011, Vol 55, Num 4, pp 866-875, issn 0168-8278, 10 p.Article

Loco-Regional Treatment of Hepatocellular Carcinoma in the Era of Molecular Targeted TherapiesLENCIONI, Riccardo.Oncology. 2010, Vol 78, pp 107-112, issn 0030-2414, 6 p., SUP1Conference Paper

Targeted Therapies in Solid Tumours: Pinpointing the Tumour's Achilles HeelKORNEK, Gabriela; SELZER, Edgar.Current pharmaceutical design (Print). 2009, Vol 15, Num 2, pp 207-242, issn 1381-6128, 36 p.Article

Anti-angiogenic and anti-HER therapyGASPARINI, Giampietro; SARMIENTO, Roberta; LONGO, Raffaele et al.Biomedicine & pharmacotherapy. 2006, Vol 60, Num 6, pp 263-265, issn 0753-3322, 3 p.Conference Paper

Molecular biology of medulloblastoma : will it ever make a difference to clinical management?GILBERTSON, Richard J; GAJJAR, Amar.Journal of neuro-oncology. 2005, Vol 75, Num 3, pp 273-278, issn 0167-594X, 6 p.Article

A report of three patients treated with Immunocell therapy with imatinib mesylateKANEKO, Toru; GOTO, Shigenori; KUSHIMA, Yoshiaki et al.Anticancer research. 2004, Vol 24, Num 5C, pp 3303-3309, issn 0250-7005, 7 p.Conference Paper

Genetic Surgery ― A Right Strategy to Attack CancerSVERDLOV, Eugene D.Current gene therapy. 2011, Vol 11, Num 6, pp 501-531, issn 1566-5232, 31 p.Article

Molecular Pathogenesis of Hepatocellular CarcinomaCORNELLA, Helena; ALSINET, Clara; VILLANUEVA, Augusto et al.Alcoholism, clinical and experimental research. 2011, Vol 35, Num 5, pp 821-825, issn 0145-6008, 5 p.Conference Paper

Molecular targets for therapeutic interventions in human papillomavirus-related cancers (Review)SAITO RAMALHO, Alan; DANTAS LOPES, Anselmo; TALANS, Aleylove et al.Oncology reports. 2010, Vol 24, Num 6, pp 1419-1426, issn 1021-335X, 8 p.Article

Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experienceMOLIFE, L. R; ALAM, S; KAYE, S. B et al.Annals of oncology. 2012, Vol 23, Num 8, pp 1968-1973, issn 0923-7534, 6 p.Article

The Role of Kinesin Family Proteins in Tumorigenesis and Progression: Potential Biomarkers and Molecular Targets for Cancer TherapyYUE YU; FENG, Yu-Mei.Cancer. 2010, Vol 116, Num 22, pp 5150-5160, issn 0008-543X, 11 p.Article

Receptor tyrosine kinase alterations and therapeutic opportunities in squamous cell carcinoma of the lungDONG WANG; LICHENG DU; QI LIU et al.Cancer chemotherapy and pharmacology. 2013, Vol 72, Num 4, pp 725-731, issn 0344-5704, 7 p.Article

Germ Cell Tumors of the Gonads : A Selective Review Emphasizing Problems in Drug Resistance and Current Therapy OptionsSCHRADER, Mark; KEMPKENSTEFFEN, Carsten; ALBERS, Peter et al.Oncology. 2009, Vol 76, Num 2, pp 77-84, issn 0030-2414, 8 p.Article

Resistance to BRAF-targeted therapy in melanomaSULLIVAN, Ryan J; FLAHERTY, Keith T.European journal of cancer (1990). 2013, Vol 49, Num 6, pp 1297-1304, issn 0959-8049, 8 p.Article

Targeting the molecular chaperone heat shock protein 90 (HSP90): Lessons learned and future directionsTONG, David S; BANERJI, Udai; TAVANA, Bahareh et al.Cancer treatment reviews. 2013, Vol 39, Num 4, pp 375-387, issn 0305-7372, 13 p.Article

Targeted therapy in haematological malignanciesHAMILTON, Ashley; GALLIPOLI, Paolo; NICHOLSON, Emma et al.Journal of pathology (Print). 2010, Vol 220, Num 4, pp 404-418, issn 0022-3417, 15 p.Article

Dermatofibrosarcoma protuberans = Dermatofibrosarcoma protuberansUGUREL, S.Hautarzt. 2008, Vol 59, Num 11, pp 933-940, issn 0017-8470, 8 p.Article

Kutane Nebenwirkungen molekular zielgerichteter Therapien = Cutaneous reactions to molecular targeted therapiesPFÖHLER, C; UGUREL, S.Hautarzt. 2008, Vol 59, Num 10, pp 814-820, issn 0017-8470, 7 p.Article

Improving the design of phase II trials of cytostatic anticancer agentsSTONE, Andrew; WHEELER, Catherine; BARGE, Alan et al.Contemporary clinical trials. 2007, Vol 28, Num 2, pp 138-145, issn 1551-7144, 8 p.Article

Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy : enhanced effects in vitro and dose-dependent growth delay in vivoMARINI, P; DENZINGER, S; SCHILLER, D et al.Oncogene (Basingstoke). 2006, Vol 25, Num 37, pp 5145-5154, issn 0950-9232, 10 p.Article

Analysis of PTEN and HIF-1α and Correlation With Efficacy in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus Versus Interferon-αFIGLIN, Robert A; DE SOUZA, Paul; HUDES, Gary et al.Cancer. 2009, Vol 115, Num 16, pp 3651-3660, issn 0008-543X, 10 p.Article

Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107)JAHAN, Thierry; LIN GU; KRATZKE, Robert et al.Lung cancer. 2012, Vol 76, Num 3, pp 393-396, issn 0169-5002, 4 p.Article